Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation.

Curr Oncol · 2025 · PMC12192008 · PMID 40558237

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

However, this lack of statistical significance may be attributed to the small sample size of the cohort with a notable trend in survival outcomes: the 2-year LFS was 62.5% for RUNX1+ versus 88.9% for RUNX1− , and the 2-year OS was 87.5% compared to 100.0%, respectively.

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.